$NRBO News Article - NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models
https://marketwirenews.com/news-releases/neur...50413.html